Enduring response to everolimus as third-line therapy in a patient with advanced renal cell carcinoma, including small-bowel metastases: loss of FHIT but normal VHL gene status

MeSH terms

• Acid Anhydride Hydrolases / genetics*
• Antineoplastic Agents / therapeutic use*
• Carcinoma, Renal Cell / diagnostic imaging
• Carcinoma, Renal Cell / drug therapy
• Carcinoma, Renal Cell / genetics
• Carcinoma, Renal Cell / secondary*
• Everolimus
• Gene Deletion
• Humans
• In Situ Hybridization, Fluorescence
• Jejunal Neoplasms / diagnostic imaging
• Jejunal Neoplasms / drug therapy
• Jejunal Neoplasms / genetics
• Jejunal Neoplasms / secondary*
• Kidney Neoplasms / diagnostic imaging
• Kidney Neoplasms / drug therapy
• Kidney Neoplasms / genetics
• Kidney Neoplasms / pathology*
• Male
• Middle Aged
• Neoplasm Proteins / genetics*
• Radiography
• Sirolimus / analogs & derivatives*
• Sirolimus / therapeutic use
• Treatment Outcome
• Von Hippel-Lindau Tumor Suppressor Protein / genetics*